SynthesisDiabetes & metabolic syndrome2022
Global reports of myocarditis following COVID-19 vaccination: A systematic review and meta-analysis.
Synthesis in Diabetes & metabolic syndrome, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 4 syntheses or guidelines pooled it, 38 citations in OpenAlex.
- Occurrence of Myocarditis in Patients Immunized with Different Types of COVID-19 Vaccines: A Systematic Review and Meta-Analysis.Virus research · 2026Pooled it
- Systematic review exploring the clinical features of optic neuritis after SARS-CoV infection and vaccination.BMJ open ophthalmology · 2023Pooled it
- Myocarditis and coronavirus disease 2019 vaccination: A systematic review and meta-summary of cases.Biomolecules & biomedicine · 2023Pooled it
- Risk of myocarditis and pericarditis in mRNA COVID-19-vaccinated and unvaccinated populations: a systematic review and meta-analysis.BMJ open · 2023Pooled it
- Investigating Parental Perception and Intentions Toward COVID-19 Vaccination for Children in Ras Al Khaimah.Health science reports · 2026Article
- "Bridging the clinical, molecular and genetic perspectives on myocarditis in post-COVID-19 era".International journal of cardiology. Cardiovascular risk and prevention · 2026Review
- Assessment of healthcare workers' knowledge and attitudes toward mpox and acceptance of its vaccine: a health belief model-based analysis in the Gulf region.Osong public health and research perspectives · 2025Article
- Article
- Review
- Cardiovascular Sequelae of the COVID-19 Vaccines.Cureus · 2025Review
- Factors associated with carditis adverse events following SARS-COV-2-19 vaccination.Epidemiology and infection · 2025Article
- COVID-19 Vaccination and Cardiovascular Events: A Systematic Review and Bayesian Multivariate Meta-Analysis of Preventive Benefits and Risks.International journal of preventive medicine · 2025Review
- Current Status and Future Trends in Myocarditis Related to the COVID-19 Vaccines: A Visual and Bibliometric Analysis.Current vascular pharmacology · 2025Article
- Myocarditis Associated with COVID-19 Vaccination.Vaccines · 2024Review
- Incidence and management of the main serious adverse events reported after COVID-19 vaccination.Pharmacology research & perspectives · 2024Review
- The laboratory parameters in predicting the severity and death of COVID-19 patients: Future pandemic readiness strategies.Biomolecules & biomedicine · 2024Review
- Pediatric Chest Pain: A Review of Diagnostic Tools in the Pediatric Emergency Department.Diagnostics (Basel, Switzerland) · 2024Review
- Uptake and cardiac events of COVID-19 vaccinations among Canadian youth and young adults.PLOS global public health · 2024Article
- Article
- Cardiovascular Disease and COVID-19 Vaccines: A Systematic Review and Analysis of Published Cases.European cardiology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsRecent media reports of myocarditis after receiving COVID-19 vaccines, particularly the messenger RNA (mRNA) vaccines, are causing public concern. This review summarizes information from published case series and case reports, emphasizing patient and disease characteristics, investigation, and clinical outcomes, to provide a comprehensive picture of the condition.
methodsA systematic literature search of PubMed and Google scholar was conducted from inception to April 27, 2022. Individuals who develop myocarditis after receiving the COVID-19 vaccine, regardless of the type of vaccine and dose, were included in the study.
resultsSixty-two studies, including 218 cases, participated in the current systematic review. The median age was 29.2 years; 92.2% were male and 7.8% were female. 72.4% of patients received the Pfizer-BioNTech (BNT162b2) vaccine, 23.8% of patients received the Moderna COVID-19 Vaccine (mRNA-1273), and the rest of the 3.5% received other types of COVID-19 vaccine. Furthermore, most myocarditis cases (82.1%) occurred after the second vaccine dose, after a median time interval of 3.5 days. The most frequently reported symptoms were chest pain, myalgia/body aches and fever. Troponin levels were consistently elevated in 98.6% of patients. The admission ECG was abnormal in 88.5% of cases, and the left LVEF was lower than 50% in 21.5% of cases. Most patients (92.6%) resolved symptoms and recovered, and only three patients died.
conclusionThese findings may help public health policy to consider myocarditis in the context of the benefits of COVID-19 vaccination.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.